Two new crown oral drugs with conditional approval for marketing!
Read Time:41 Second
Recently, the State Drug Administration, in accordance with the relevant provisions of the Drug Administration Law, conducted emergency review and approval in accordance with the special drug approval procedures, and conditionally approved the Class 1 innovative drug centronavir tablets/ritonavir tablets combination package (trade name: Centronoxin) declared by Hainan Centron Pharmaceutical Co. (trade name: Mindvir) to market.
Both of these drugs are oral small molecule neocoronavirus infection treatment drugs for adult patients with mild to moderate novel coronavirus infection (COVID-19). Patients should use the drugs strictly according to the instructions under the guidance of a physician.
The State Drug Administration requires the holder of the marketing license to continue the relevant research work, complete the requirements of the attached conditions by the deadline, and submit the results of the follow-up study in a timely manner.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating